Showing results (21-30 of 54) with videos related to
Sort By:
Pageof 6
American Journal of Hematology|August 21, 2013
Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphomaJeffrey A Jones, Amy S Rupert, Ming Poi, et al.Clinical Lymphoma, Myeloma & Leukemia|February 10, 2015
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphomaJonathon B Cohen, Amy S Ruppert, Nyla A Heerema, et al.Experimental Hematology|May 5, 2015
ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivoRajeswaran Mani, Chi-Ling Chiang, Frank W Frissora, et al.Leukemia Research|July 23, 2013
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemiaDeborah M Stephens, Amy S Ruppert, Kami Maddocks, et al.Molecular Therapy Oncolytics|August 17, 2017
Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell CarcinomaAlena C Jaime-Ramirez, Jun-Ge Yu, Enrico Caserta, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|February 4, 2026
Clinical characteristics associated with terminal methotrexate clearance in patients with non-Hodgkin lymphomas receiving high-dose methotrexateZachary J Arnold, Jordan Lundberg, Tracy Wiczer, et al.Investigational New Drugs|October 13, 2010
A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumorsBhuvaneswari Ramaswamy, Mitch A Phelps, Robert Baiocchi, et al.British Journal of Haematology|May 12, 2010
Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylationKristie A Blum, Zhongfa Liu, David M Lucas, et al.Cancer Medicine|January 19, 2023
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agentsMuhammad Salman Faisal, Walter Hanel, Timothy Voorhees, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 26, 2021
Aging Phenotypes and Restoring Functional Deficits in Older Adults With Hematologic MalignancyAshley E Rosko, Sarah Wall, Robert Baiocchi, et al.Pageof 6